Exploring Privileged Heterocyclic Scaffolds: : Their Scope as Novel Anti-Inflammatory Drug Candidates

ISBN-13: 9786139900893 / Angielski / Miękka / 2018 / 88 str.

Rajeev Kharb

Opis

Inflammation is characterized by redness, heat, swelling, pain and sometimes loss of function of tissues. Cyclooxygenases (COXs) are mainly responsible for inflammation. Constitutive COX-1 is responsible for providing cytoprotection in gastrointestinal (GI) tract whereas inducible COX-2 facilitates inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat the signs and symptoms of inflammation. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as Aspirin, Diclofenac, Flurbiprofen and Ibuprofen act via the inhibition of the COX-1 isoenzyme or the combined inhibition of COX-1 and COX-2 isoenzymes. However they show greater selectivity for COX-1 than COX-2 as well as produce serious side effect like hepatic toxicity. Therefore, it is urgently required to identify new targets that are essential for the design and development of novel anti-inflammatory agents as an alternative to NSAIDs. The relevant information provided in this manuscript can be found useful for drug design of novel anti-inflammatory agents having greater safety, selectivity and potency as well as lesser side effects.

O autorze

Kharb, Rajeev
Dr. Rajeev Kharb is working as Associate Professor in Amity Institute of Pharmacy, Amity University, Noida, India. He has 14 years of experience in teaching and research. He has 30 publications and written 3 books. His area of research is design and synthesis of novel anti-inflammatory and antimicrobial compounds.